ESCMID works throughout the year to propose and endorse quality guidelines to members and the global professional community. Below is a list of guidance documents that are currently under development. Explore the details of each guidance document and follow the evolution of their progress via the links provided.
The status of each project is defined based on the steps of the GIN-McMaster Guideline Development Checklist.
|
Title |
Chair |
Approval Date |
Status |
Website |
|---|---|---|---|---|
|
Infection control strategies and interventions to prevent ventilator-associated pneumonia in adult patients |
Gabriel Birgand, France and Henri van Werkhoven, Netherlands |
February 2025 |
Literature searches (ongoing) |
|
|
Selection and duration of antibiotic treatment in infectious aortitis and vascular graft and endograft infections |
Marjan Wouthuyzen-Bakker, Netherlands |
February 2025 |
Screening of literature (ongoing) |
|
|
Nomenclature, diagnosis and treatment of acute and chronic Q fever |
Chantal Rovers, Netherlands |
February 2025 |
Literature searches (ongoing) |
|
|
The update of the 2021 ESCMID guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli |
Mical Paul, Israel |
February 2025 |
Screening of literature and data extraction (ongoing) |
|
|
Approach to suspected antibiotic allergy |
Mark de Boer, Netherlands |
March 2023 |
Reporting and Peer Review (Ongoing) |
|
|
Vaccination of the immunocompromised host |
Olivier Epaulard, France |
March 2023 |
Reporting and Peer Review (Ongoing) |
|
|
Dosing of antimicrobials in patients with renal impairment with or without RRT |
Thomas Tängdén, Sweden |
March 2023 |
Summarizing Evidence and Judging Quality, Strength or Certainty of a Body of Evidence (GRADE) (Ongoing) |
|
|
Update of the 2014 ESCMID guidelines for the management of the infection prevention & control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients |
Evelina Tacconelli, Italy |
December 2020 |
Judging Quality, Strength or Certainty of a Body of Evidence (GRADE) (ongoing) |
|
|
Diagnosis and management of infective encephalitis (ESCMID/EAN) |
Thomas Whitfield, United States (ESCMID representative) |
April 2018 |
Reporting (Ongoing) (September 2025) |
|
|
Management of Staphylococcus aureus bacteremia (IDSA/ESCMID) |
Winfried Kern, Germany and François Vandenesch, France |
January 2017 |
Developing Recommendations and Determining their Strength (EtDs) (March 2024) |
|
There are currently no documents under public consideration.
Please check back in at a later date if you wish to participate in the future.